The Systemic Immune-Inflammation Index as an Independent Predictor of Survival in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Radiotherapy

References

• Erratum. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca a Cancer J Clinicians. 2020;70:313.
   Web of Science ®Google Scholar
• Morgan E, Soerjomataram I, Rumgay H, et al. the global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163:649–658.e2. doi:10.1053/j.gastro.2022.05.054
   PubMed Web of Science ®Google Scholar
• Leng X, Daiko H, Han Y, Mao Y. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma. Ann NY Acad Sci. 2020;1482:213–224. doi:10.1111/nyas.14508
   PubMed Web of Science ®Google Scholar
• Klevebro F, Johnsen G, Johnson E, et al. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: a randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. European j Surg Oncol. 2015;41:920–926. doi:10.1016/j.ejso.2015.03.226
   PubMed Web of Science ®Google Scholar
• Stahl M, Walz M, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–856. doi:10.1200/JCO.2008.17.0506
   PubMed Web of Science ®Google Scholar
• Burmeister B, Thomas J, Burmeister E, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised Phase II trial. Eur J Canc. 2011;47:354–360. doi:10.1016/j.ejca.2010.09.009
   PubMed Web of Science ®Google Scholar
• Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Annals of Oncology. 2023;34:163–172. doi:10.1016/j.annonc.2022.10.508
   PubMedGoogle Scholar
• Zhang S, Du J, Zhong X, et al. The prognostic value of the systemic immune-inflammation index for patients with bladder cancer after radical cystectomy. Front Immunol. 2022;13:1072433. doi:10.3389/fimmu.2022.1072433
   PubMed Web of Science ®Google Scholar
• Tanaka S, Uchino J, Yokoi T, et al. Prognostic nutritional index and lung immune prognostic index as prognostic predictors for combination therapies of immune checkpoint inhibitors and cytotoxic anticancer chemotherapy for patients with advanced non-small cell lung cancer. Diagnostics. 2022; 12. doi:10.3390/diagnostics13010012
   Web of Science ®Google Scholar
• Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019;9:3284. doi:10.1038/s41598-019-39150-0
   PubMed Web of Science ®Google Scholar
• Polk N, Budai B, Hitre E, Patócs A, Mersich T. Corrigendum: High Neutrophil-to-Lymphocyte Ratio (NLR) and systemic immune-inflammation index (SII) are markers of longer survival after metastasectomy of patients with liver-only metastasis of rectal cancer. Pathol Oncol Res. 2022;28:1610658. doi:10.3389/pore.2022.1610658
   PubMed Web of Science ®Google Scholar
• Ma Y, Chen J, Yao X, et al. Patterns and prognostic predictive value of perineural invasion in esophageal squamous cell carcinoma. BMC Cancer. 2022;22:1287. doi:10.1186/s12885-022-10386-w
   PubMed Web of Science ®Google Scholar
• Wu X, Han R, Zhong Y, Weng N, Zhang A. Correction to: post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Can Cell Inter. 2021;21:693. doi:10.1186/s12935-021-02401-0
   PubMed Web of Science ®Google Scholar
• Xiao F, Wang L, Zhang W, Wang L, Zhao L. Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival in Esophageal Squamous Cell Carcinoma Patients. Nutr Canc. 2021;73:215–220. doi:10.1080/01635581.2020.1757129
   PubMed Web of Science ®Google Scholar
• Feng J, Chen S, Yang X. Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus. Medicine. 2017;96:e5886. doi:10.1097/MD.0000000000005886
   PubMed Web of Science ®Google Scholar
• Joseph E DL, Beverly RKW, Leo TF. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10:10.
   Web of Science ®Google Scholar
• Joseph CYC, David LC, Connie I D, et al. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg. 2016;265:539.
   Web of Science ®Google Scholar
• Ben ZS, Mark LK. Platelets and tumor cells: a new form of border control. Cancer Cell. 2013;24:24.
   Web of Science ®Google Scholar
• Zhang Y, Liu X, Xu M, Chen K, Li S, Guan G. Prognostic value of pretreatment systemic inflammatory markers in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Sci Rep. 2020;10:8017. doi:10.1038/s41598-020-64684-z
   PubMed Web of Science ®Google Scholar
• Mirili C, Paydas S, Kapukaya T, Yılmaz A. Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma. Biomarkers Med. 2019;13:1565–1575. doi:10.2217/bmm-2019-0303
   PubMed Web of Science ®Google Scholar
• Coutu B, Johnson K, Bhirud A, et al. Systemic Immune-Inflammatory Index Association with Survival in Patients Undergoing Trimodality Therapy for Lung Cancer. Oncology. 2022;100:247–256. doi:10.1159/000520989
   PubMed Web of Science ®Google Scholar
• Li J, Cao D, Huang Y, et al. The Prognostic and Clinicopathological Significance of Systemic Immune-Inflammation Index in Bladder Cancer. Front Immunol. 2022;13:865643. doi:10.3389/fimmu.2022.865643
   PubMed Web of Science ®Google Scholar
• Chang L, Cheng Q, Ma Y, et al. Prognostic Effect of the Controlling Nutritional Status Score in Patients With Esophageal Cancer Treated With Immune Checkpoint Inhibitor. J Immunother. 2022;45:415–422. doi:10.1097/CJI.0000000000000438
   PubMed Web of Science ®Google Scholar
• Stanger BZ, Kahn ML. Platelets and tumor cells: a new form of border control. Cancer Cell. 2013;24:9–11. doi:10.1016/j.ccr.2013.06.009
   PubMed Web of Science ®Google Scholar
• Ma C, Fu Q, Diggs L, et al. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Canc Cell. 2022;40:986–998.e5. doi:10.1016/j.ccell.2022.08.004
   PubMed Web of Science ®Google Scholar
• Franco A, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126:582–588. doi:10.1182/blood-2014-08-531582
   PubMed Web of Science ®Google Scholar
• Tan K, Chong S, Wong F, et al. Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D. Blood. 2013;122:3666–3677. doi:10.1182/blood-2012-11-466532
   PubMed Web of Science ®Google Scholar
• Park J, Wysocki R, Amoozgar Z, et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci trans med. 2016;8:361ra138. doi:10.1126/scitranslmed.aag1711
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang F, Sheng X, Zhang S. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ib1-IIa cervical cancer patients who undergo radical surgery. Onco Targets Ther. 2015;8:1355–1362. doi:10.2147/OTT.S82174
   PubMed Web of Science ®Google Scholar
• Maquilan G, Grover S, Xanthopoulos E, et al. Analysis of the relationship between response to chemotherapy and response to radiation therapy in patients with non-small cell lung cancer receiving sequential treatment. American j Clin Oncol. 2018;41:391–395. doi:10.1097/COC.0000000000000288
   PubMed Web of Science ®Google Scholar
• Wei-Xiang Q, Xiaoyan W, Chengqiang L, et al. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: an analysis from a prospective cohort. Thorac Canc. 2023;14.
   Web of Science ®Google Scholar
• Zhao M, Gao Z, Gu X, Yang X, Wang S, Fu J. Predictive significance of lymphocyte level and neutrophil-to-lymphocyte ratio values during radiotherapy in cervical cancer treatment. Canc Med. 2023;12:15820–15830. doi:10.1002/cam4.6221
   PubMed Web of Science ®Google Scholar
• Wang P, Wang Z, Liu Y, Xie J, Ren Y. Prognostic value of platelet-associated biomarkers in rectal cancer patients received neoadjuvant chemoradiation: a retrospective study. Canc Radiotherap. 2021;25:147–154. doi:10.1016/j.canrad.2020.06.030
   PubMed Web of Science ®Google Scholar
• Sun Y, Huang Z, Chi P. An inflammation index-based prediction of treatment response to neoadjuvant chemoradiotherapy for rectal mucinous adenocarcinoma. Int J Clin Oncol. 2020;25:1299–1307. doi:10.1007/s10147-020-01670-5
   PubMed Web of Science ®Google Scholar